Sangamo Therapeutics (SGMOQ) EBT Margin (2010 - 2025)
Sangamo Therapeutics (SGMOQ) posted EBT Margin of 266.88% for Q4 2025, up 95.58% on a QoQ basis from 6039.76% in Q3 2025, and up 9963.0% year-over-year from N/an in Q4 2024.
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) EBT Margin (2010 - 2025) Analysis & Trends
Sangamo Therapeutics has reported EBT Margin for 16 years, with the latest figure at 266.88% in Q4 2025.
- On a quarterly basis, EBT Margin rose 9963.0% year-over-year to 266.88% in Q4 2025; TTM through Dec 2025 was 312.25%, a 13937.0% decrease from a year earlier, with the FY2025 full-year figure at 312.25%, down 14251.0% from the prior year.
- EBT Margin was 266.88% for Q4 2025 at Sangamo Therapeutics, up from 6039.76% in the prior quarter.
- The five-year high for EBT Margin was 21.78% in Q3 2024, with the low at 10185.24% in Q1 2024.
- Average EBT Margin over 5 years is 1734.89%, with a median of 195.35% recorded in 2022.
- The sharpest annual moves came in 2024 and 2025: EBT Margin sank 1019874 bps in 2024, then soared 1001850 bps in 2025.
- Over 5 years, EBT Margin stood at 134.22% in 2021, then slumped by 41 bps to 189.92% in 2022, then tumbled by 1462 bps to 2966.06% in 2023, then jumped by 88 bps to 366.51% in 2024, then climbed by 27 bps to 266.88% in 2025.
- The last three EBT Margin figures came in at 266.88% (Q4 2025), 6039.76% (Q3 2025), and 109.03% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 55.43% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -885.91% |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -49.02% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 14.32% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -1,356.24% |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -24,299.18% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -0.44% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 2.88% |
| 10 | Sangamo Therapeutics | 43.74 Mn | 22.79 Mn | - | -266.88% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -266.88% |
| Sep 30, 2025 | -6,039.76% |
| Jun 30, 2025 | -109.03% |
| Mar 31, 2025 | -473.48% |
| Dec 31, 2024 | -366.51% |
| Sep 30, 2024 | 21.78% |
| Jun 30, 2024 | -10,127.53% |
| Mar 31, 2024 | -10,185.24% |
| Dec 31, 2023 | -2,966.06% |
| Sep 30, 2023 | -1,094.84% |
| Jun 30, 2023 | -1,766.93% |
| Mar 31, 2023 | 13.50% |
| Dec 31, 2022 | -189.92% |
| Sep 30, 2022 | -200.77% |
| Jun 30, 2022 | -146.68% |
| Mar 31, 2022 | -155.57% |
| Dec 31, 2021 | -134.22% |
| Sep 30, 2021 | -166.66% |
| Jun 30, 2021 | -169.17% |
| Mar 31, 2021 | -173.81% |